Spotlight on the Fear of Cancer Recurrence Inventory (FCRI)
Open accessThe DOI matches its Crossref record; 81 of the 82 references it cites were found in a registry or an index; 3 of the 110 sources its claims cite were checked for support.
Abstract
Fear of cancer recurrence (FCR) is a pervasive concern for people living with cancer. The rapidly expanding FCR literature has been weakened somewhat by use of miscellaneous FCR measures of varying quality. The Fear of Cancer Recurrence Inventory (FCRI) has been widely used in observational and intervention studies and the FCRI severity subscale, also known as the FCRI-Short Form (FCRI-SF), is often used to identify potential cases of clinically significant FCR. Given the FCRI's increasing use in research and clinical practice, we aimed to provide an overview, critique, and suggested improvements of the FCRI. Studies citing the original FCRI validation paper were identified and synthesised using narrative and meta-analytic methods. The 42-item FCRI has demonstrated a reasonably robust 7-factor structure across evaluations in multiple languages, although certain subscales (eg, Coping) demonstrate sub-optimal reliability. Confirmation of the cross-cultural equivalence of several FCRI translations is needed. Meta-analysis of FCRI-SF scores revealed a combined weighted mean score of 15.7/36, a little above the lowest proposed cut-off score (≥13) for clinical FCR. Depending on the FCRI-SF cut-off used, between 30.0% and 53.9% of the cancer population (ie, patients and survivors) appear to experience sub-clinical or clinical FCR. Higher FCRI scores were associated with younger age and female gender, pain/physical symptoms and psychological morbidity, consistent with the FCR literature generally. Issues regarding the application and interpretation of the FCRI remain. Whether the FCRI is well suited to assessing fear of progression as well as recurrence is unclear, the meaningfulness of the FCRI total score is debatable, and the use of the FCRI-SF to screen for clinical FCR is problematic, as items do not reflect established characteristics of clinical FCR. Refinement of the FCRI is needed for it to remain a key FCR assessment tool in future research and clinical practice.
Overview
CoChat Summary
## TL;DR
This state-of-the-art review synthesizes 198 articles citing the original FCRI validation paper and concludes that the 42-item FCRI has reasonably robust psychometric support, but some subscales and the short form have important limitations. The meta-analysis found a weighted mean FCRI-SF score of 15.7/36, with 30.0% to 53.9% of the cancer population scoring at or above proposed clinical cut-offs depending on which threshold was used.
## Key findings
- The review identified 198 articles citing the original FCRI validation paper; 18 studies were included in the narrative synthesis of factor structure and psychometrics, and 46 studies in the meta-analysis of prevalence/severity.
- Across 46 independent samples from 14,092 cancer patients and survivors, the aggregated weighted mean FCRI-SF score was 15.8 (95% CI: 14.5–17.1); the aggregated weighted mean FCRI-Total score was 65.2 (95% CI: 58.0–72.3).
- Depending on the FCRI-SF cut-off, 53.9% of participants scored above ≥13, 43.3% above ≥16, and 30% above ≥22.
- Reliability was generally good, with a weighted pooled test–retest correlation of 0.89 (95% CI: 0.80–0.98), but the Reassurance and Coping Strategies subscales were repeatedly described as less than ideal/sub-optimal.
- Meta-regression found higher FCRI-SF scores in English-language samples (18.0; 95% CI: 16.0–20.0) than non-English samples (14.3; 95% CI: 12.9–15.7; Beta=3.7, p=0.003), and a small positive association between FCRI-SF scores and time since diagnosis (Beta=0.05, p=0.049).
## Methods
- State-of-the-art review with three components: narrative synthesis of factor structure/psychometrics and correlates, meta-analysis of FCR prevalence and severity, and discussion of limitations/improvements.
- Literature search used Scopus only, identifying peer-reviewed English-language articles from March 2009 to March 2020 that cited the original FCRI validation paper; all article types were eligible for the narrative review, and article quality was not assessed.
- Meta-analytic outcomes were mean FCRI total scores, mean FCRI-SF scores, and percentages above FCRI-SF cut-offs of ≥13, ≥16, or ≥22; analyses used random effects models, with subgroup analyses/meta-regression when heterogeneity was present.
## Limitations
- The paper states that cross-cultural equivalence has been established for only two translations, and that more work is needed to confirm equivalence across the many FCRI translations.
- The authors note that the FCRI-SF cut-offs vary and that the short form may have low specificity and may not map well onto established characteristics of clinical FCR.
- Evident from the text: the review searched only Scopus and included only English-language papers, and article quality was not assessed; the meta-analysis also relied heavily on samples from intervention studies, which the authors say may not represent the broader cancer population.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
3 Valid · 3 Not valid · 51 Not checked · 64 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Cross-cultural equivalence has been established for two FCRI translations: the English translation, by means of a repeated-measures analysis of variance (in 42 cancer patients),14 and the Korean translation, by means of ranking similarity of FCRI items on a 7-point Likert scale (in 6 cancer patients, 8 nurses, and 18 physicians).19”
§ Spotlight on the Fear of Cancer Recurrence Inventory (FCRI) > Results and Discussion > FCRI Factor Structure and Psychometric Properties
What the sources say
- Supportedcites [19] Shin, 2017, J Korean Med Sci source
The Methods subsection 'Cross-cultural validity and reliability' (p. 1) states that thirty-two bilinguals composed of six cancer patients, eight nurses, and 18 physicians assessed the cultural equivalence of the K-FCRI against the original English FCRI, and that similarity (of language comparability and interpretability) was quantified on a Likert scale from one to seven, with mean scores of 1.34 and 1.49 leading the authors to confirm cultural equivalence. The Abstract and Discussion likewise report good cross-cultural equivalence between the Korean and English versions. (LLM, conf=0.92)
plainn = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“According to Ponterotto and Charter’s guidelines,25 the internal consistencies of the Reassurance and Coping Strategies subscales in several studies11,13,14,18,19,23,24,26 can be categorized as fair or moderate, which corroborates with other empirical analyses22,27 suggesting problematic features of these subscales.”
§ Spotlight on the Fear of Cancer Recurrence Inventory (FCRI) > Results and Discussion > FCRI Factor Structure and Psychometric Properties
What the sources say
- Not checked yetcites [11] Simard, 2009, Support Care Cancer source
- Not checked yetcites [13] Simard, 2010, J Cancer Surviv source
- Not checked yetcites [14] Lebel, 2016, Qual Life Res source
- Not checked yetcites [18] van Helmondt, 2017, J Psychosom Res source
- Partly supportedcites [19] Shin, 2017, J Korean Med Sci sourceExperimental — accuracy not yet measured
The Results section of the K-FCRI validation reports internal consistency for all seven subscales, including reassurance and coping strategies: Cronbach's alphas of 0.77–0.84, which the authors themselves describe as 'within acceptable to good levels' — so this paper does supply subscale-level reliability data, but its values and characterisation do not match the 'fair or moderate' categorisation the citing sentence applies to it. The only subscale-specific figures in our copy (reassurance α = 0.75, coping strategies α = 0.89) appear in Methods ('Translation and pilot test') and are explicitly credited to a previous validation study (reference 8, the original French-Canadian FCRI), not to this study's own data. Our copy also never invokes Ponterotto and Charter's guidelines; the paper's Discussion characterises these subscales' weakness in terms of low-to-moderate correlations with the total score, not low internal consistency. (LLM, conf=0.70)
- Not checked yetcites [23] van Helmondt, 2020, Eur J Cancer Care (Engl)
- Not checked yetcites [24] Galica, 2018, Psychooncology source
- Not checked yetcites [26] Custers, 2017, J Cancer Surviv source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The total score certainly captures far more than FCR, as it is commonly defined,1 and even if data are able to support a higher-order factor capturing shared variance in the seven subscales, it is unclear what this higher order factor represents.”
§ Spotlight on the Fear of Cancer Recurrence Inventory (FCRI) > Results and Discussion > FCRI Limitations and Future Directions
What the sources say
- Partly supportedcites [1] Lebel, 2016, Support Care Cancer sourceExperimental — accuracy not yet measured
The Results (p. 4) define FCR as fear, worry, or concern about cancer returning or progressing, supporting the definition used in the comparison. The paper does not assess what the FCRI total score captures, so it does not establish that the score captures far more than FCR. (LLM, conf=0.84)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Higher FCRI scores were associated with younger age and female gender, pain/physical symptoms and psychological morbidity, consistent with”
§ Spotlight on the Fear of Cancer Recurrence Inventory (FCRI) > Abstract Fear of cancer recurrence (FCR) is a pervasive concern for people living with cancer. The rapidly expanding FCR literature has been weakened somewhat by use of miscellaneous FCR measures of varying quality. The Fear of Cancer Recurrence Inventory (FCRI) has been widely used in observational and intervention studies and the FCRI severity subscale, also known as the FCRI-Short Form (FCRI-SF), is often used to identify potential cases of clinically significant FCR. Given the FCRI’s increasing use in research and clinical practice, we aimed to provide an overview, critique, and suggested improvements of the FCRI. Studies citing the original FCRI validation paper were identified and synthesised using narrative and meta-analytic methods. The 42-item FCRI has demonstrated a reasonably robust 7-factor structure across evaluations in multiple languages, although certain subscales (eg, Coping) demonstrate sub-optimal reliability. Confirmation of the cross-cultural equivalence of several FCRI translations is needed. Meta-analysis of FCRI-SF scores revealed a combined weighted mean score of 15.7/36, a little above the lowest proposed cut-off score (≥13) for clinical FCR. Depending on the FCRI-SF cut-off used, between 30.0% and 53.9% of the cancer population (ie, patients and survivors) appear to experience sub-clinical or clinical FCR. Higher FCRI scores were associated with younger age and female gender, pain/physical symptoms and psychological morbidity, consistent with the FCR literature generally. Issues regarding the application and interpretation of the FCRI remain. Whether the FCRI is well suited to assessing fear of progression as well as recurrence is unclear, the meaningfulness of the FCRI total score is debatable, and the use of the FCRI-SF to screen for clinical FCR is problematic, as items do not reflect established characteristics of clinical FCR. Refinement of the FCRI is needed for it to remain a key FCR assessment tool in future research and clinical practice.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 42-item FCRI has demonstrated a reasonably robust 7-factor structure across evaluations in multiple languages, although certain subscales (eg, Coping) demonstrate sub-optimal reliability.”
§ Spotlight on the Fear of Cancer Recurrence Inventory (FCRI) > Abstract Fear of cancer recurrence (FCR) is a pervasive concern for people living with cancer. The rapidly expanding FCR literature has been weakened somewhat by use of miscellaneous FCR measures of varying quality. The Fear of Cancer Recurrence Inventory (FCRI) has been widely used in observational and intervention studies and the FCRI severity subscale, also known as the FCRI-Short Form (FCRI-SF), is often used to identify potential cases of clinically significant FCR. Given the FCRI’s increasing use in research and clinical practice, we aimed to provide an overview, critique, and suggested improvements of the FCRI. Studies citing the original FCRI validation paper were identified and synthesised using narrative and meta-analytic methods. The 42-item FCRI has demonstrated a reasonably robust 7-factor structure across evaluations in multiple languages, although certain subscales (eg, Coping) demonstrate sub-optimal reliability. Confirmation of the cross-cultural equivalence of several FCRI translations is needed. Meta-analysis of FCRI-SF scores revealed a combined weighted mean score of 15.7/36, a little above the lowest proposed cut-off score (≥13) for clinical FCR. Depending on the FCRI-SF cut-off used, between 30.0% and 53.9% of the cancer population (ie, patients and survivors) appear to experience sub-clinical or clinical FCR. Higher FCRI scores were associated with younger age and female gender, pain/physical symptoms and psychological morbidity, consistent with the FCR literature generally. Issues regarding the application and interpretation of the FCRI remain. Whether the FCRI is well suited to assessing fear of progression as well as recurrence is unclear, the meaningfulness of the FCRI total score is debatable, and the use of the FCRI-SF to screen for clinical FCR is problematic, as items do not reflect established characteristics of clinical FCR. Refinement of the FCRI is needed for it to remain a key FCR assessment tool in future research and clinical practice.
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
56 more claims
Create a free account to see all 121 claims and to verify the 107 references still open.
- It may state two separate claims as one. 49
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This rate is higher than those obtained in previous studies of patients treated for cancer (e.g., breast, lung, pancreatic, endometrial) also using the FCRI-S, which ranged from 53.1 to 60.1% [51].”
From Fear of cancer recurrence in breast cancer survivors carrying a BRCA1 or 2 genetic mutation : a cross-sectional study (2024) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Associations with other factors such as sleep quality, cancer type, and time since cancer diagnosis or treatment have also been investigated, but have yielded inconclusive results.”
From What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta‐analysis (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The higher percentage scoring ≥22 in the meta‐analysis is most likely due to a difference in inclusion criteria.”
From What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta‐analysis (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The severity subscale (range 0–36) is widely used as a short form of the FCRI (FCRI‐SF) and was also used as the primary outcome in this study, because the total score includes several aspects other than severity.”
From What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta‐analysis (2022) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“A recent meta‐analysis of FCRI results found that 53.9% of cancer survivors and patients scored above the ≥13 cut‐off, 43.3% above the ≥16 cut‐off, and 30% above the ≥22 cut‐off on the FCRI severity subscale.”
From What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta‐analysis (2022) · cites this paper as [23]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Spotlight on the Fear of Cancer Recurrence Inventory (FCRI) > Abstract
“Depending on the FCRI-SF cut-off used, between 30.0% and 53.9% of the cancer population (ie, patients and survivors) appear to experience sub-clinical or clinical FCR.”
§ Spotlight on the Fear of Cancer Recurrence Inventory (FCRI) > Conclusion
“Depending on the FCRI-SF cut-off used, between 30.0% and 53.9%of the cancer population (ie patients and survivors) seemingly experience clinical FCR.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Spotlight on the Fear of Cancer Recurrence Inventory (FCRI) > Abstract
“Meta-analysis of FCRI-SF scores revealed a combined weighted mean score of 15.7/36, a little above the lowest proposed cut-off score (≥13) for clinical FCR.”
§ Spotlight on the Fear of Cancer Recurrence Inventory (FCRI) > Results and Discussion > FCR Severity and Prevalence According to the FCRI
“As seen in Table 1, the aggregated, weighted mean FCRI-SF score was 15.8 (95% CI: 14.5–17.1), which is above the lowest proposed cut-off (≥13) for clinical FCR.”
Citations
Cites
A typology of reviews: an analysis of 14 review types and associated methodologies
Grant, M. J., & Booth, A. (2009) · Health Information & Libraries Journal · doi:10.1111/j.1471-1842.2009.00848.x · Cited by 10,817
Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies
Simard, S., Thewes, B., Humphris, G., Dixon, M., Hayden, C., Mireskandari, S., & Ozakinci, G. (2013) · Journal of Cancer Survivorship · doi:10.1007/s11764-013-0272-z · Cited by 1,217 · cited 5×
“FCR Severity and Prevalence According to the FCRI A comprehensive 2013 systematic review of the literature found that 22% to 87% of cancer survivors reported moderate to high levels of FCR, and that high levels were experienced by between 0% and up to 15%.(2) These estimates were based on several heterogeneous FCR mea…”
BackgroundMethodInfluentialSimard, S., & Savard, J. (2009) · Supportive Care in Cancer · doi:10.1007/s00520-008-0444-y · Cited by 608 · cited 7×
“They used the following definition of FCR to develop the initial pool of items: the fear or worry of the possibility that the cancer will return or progress in the same organ or in another part of the body.(11,12) They generated items (n=75) based on a literature review, a cognitive-behavioral conceptualization of FCR…”
BackgroundMethodInfluentialLebel, S., Ozakinci, G., Humphris, G., Mutsaers, B., Thewes, B., Prins, J., Dinkel, A., Butow, P., & on behalf of the University of Ottawa Fear of Cancer Recurrence Colloquium attendees (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3272-5 · Cited by 586 · cited 1×
“Introduction Fear of cancer recurrence (FCR) is defined as the fear, worry, or concern that cancer may come back or progress.(1) Managing FCR is the number one unmet need of cancer survivors post cancer treatment.”
BackgroundSelf-citationWhat Is Sufficient Evidence for the Reliability and Validity of Patient-Reported Outcome Measures?
Frost, M. H., Reeve, B. B., Liepa, A. M., Stauffer, J. W., & Hays, R. D. (2007) · Value in Health · doi:10.1111/j.1524-4733.2007.00272.x · Cited by 572
Koch, L., Jansen, L., Brenner, H., & Arndt, V. (2013) · Psycho-Oncology · doi:10.1002/pon.3022 · Cited by 511
Vickberg, S. M. J. (2003) · Annals of Behavioral Medicine · doi:10.1207/s15324796abm2501_03 · Cited by 468 · cited 1×
“They used the following definition of FCR to develop the initial pool of items: the fear or worry of the possibility that the cancer will return or progress in the same organ or in another part of the body.(11,12) They generated items (n=75) based on a literature review, a cognitive-behavioral conceptualization of FCR…”
MethodFactors reported to influence fear of recurrence in cancer patients: a systematic review
Crist, J. V., & Grunfeld, E. A. (2013) · Psycho-Oncology · doi:10.1002/pon.3114 · Cited by 431
Tauber, N. M., O’Toole, M. S., Dinkel, A., Galica, J., Humphris, G., Lebel, S., Maheu, C., Ozakinci, G., Prins, J., Sharpe, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00572 · Cited by 402 · cited 1×
“Research on FCR is growing rapidly, with increasing data on its prevalence, correlates and treatment across cancer types.(2,9) Efforts to systematically capture FCR have been hampered by a lack of agreement regarding a gold standard measure and use of miscellaneous assessment tools of variable quality.”
BackgroundSelf-citationScreening and comorbidity of clinical levels of fear of cancer recurrence
Simard, S., & Savard, J. (2015) · Journal of Cancer Survivorship · doi:10.1007/s11764-015-0424-4 · Cited by 329 · cited 3×
“It manifests itself on a continuum with an estimated 49% of cancer survivors reporting moderate to severe levels of FCR,(2) often referred to as clinical FCR.(3) FCR does not appear to decrease over time, and thus if left unaddressed, it can become a lifelong concern.”
BackgroundInfluential
Research works printed but not linked: 2
- Bateni, Arch Breast Cancer, 6, 174, 10.19187/abc.201964174-180 · doi:10.19187/abc.201964174-180
- van Helmondt, 2020, Eur J Cancer Care (Engl)
Cited by
Luigjes‐Huizer, Y. L., Tauber, N. M., Humphris, G., Kasparian, N. A., Lam, W. W. T., Lebel, S., Simard, S., Smith, A. B., Zachariae, R., Afiyanti, Y., et al. (2022) · Psycho-Oncology · doi:10.1002/pon.5921 · Cited by 332
“60–74 years 1522 (51) 383 (13) 684 (23) 382 (13) 419 (48) 133 (15) 207 (24) 106 (12)”
InfluentialSelf-citationAnxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline
Grassi, L., Caruso, R., Riba, M. B., Lloyd-Williams, M., Kissane, D., Rodin, G., McFarland, D., Campos-Ródenas, R., Zachariae, R., Santini, D., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101155 · Cited by 316
“Data show that 40%-50% of cancer survivors report moderate to severe levels of FCR.24 While a certain level of worry may be adaptive, more intense episodes of FCR can compromise psychological functioning and QoL, exacerbate anxiety, cause sleep disturbances and favour the onset of depression.25 Death anxiety,26 which…”
MethodInfluentialSelf-citationChan, R. J., Crawford-Williams, F., Crichton, M., Joseph, R., Hart, N. H., Milley, K., Druce, P., Zhang, J., Jefford, M., Lisy, K., et al. (2023) · Journal of Cancer Survivorship · doi:10.1007/s11764-021-01128-1 · Cited by 192
“Additionally, the impact of different models of follow-up care on fear of cancer recurrence, which is one of the most common and debilitating concerns among cancer survivors post-treatment [46], was only reported in one review [28].”
BackgroundWilliams, J. T. W., Pearce, A., & Smith, A. '. (2021) · Psycho-Oncology · doi:10.1002/pon.5673 · Cited by 95
“The FCRI is a widely used 42‐item multi‐ dimensional FCR measure with strong psychometric properties.(36,37) One study did not use a validated FCR measure.”
MethodSelf-citationFear of Cancer Recurrence or Progression: What Is It and What Can We Do About It?
Bergerot, C. D., Philip, E. J., Bergerot, P. G., Siddiq, N., Tinianov, S., & Lustberg, M. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100031 · Cited by 90
Smith, A. ‘., Wu, V. S., Lambert, S., Lamarche, J., Lebel, S., Leske, S., & Girgis, A. (2022) · Journal of Cancer Survivorship · doi:10.1007/s11764-021-01109-4 · Cited by 48
“Keywords Cancer · Survivorship · Fear of cancer recurrence · Caregivers · Oncology · Systematic review Introduction Fear of cancer recurrence (FCR) refers to the ‘fear, worry or concern that cancer will come back or progress’ [1], which is highly prevalent among cancer survivors, irrespective of their cancer type, tim…”
BackgroundSelf-citationPeng, L., Yang, Y., Chen, M., Xu, C., Chen, Y., Liu, R., Cao, X., & Li, M. (2022) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2022.101686 · Cited by 39
Fear of Recurrence in Young Adult Cancer Patients—A Network Analysis
Richter, D., Clever, K., Mehnert-Theuerkauf, A., & Schönfelder, A. (2022) · Cancers · doi:10.3390/cancers14092092 · Cited by 44
“These varying prevalence rates are in part due to disagreement in the literature regarding a clinically relevant cut-off for FCR [32,33].”
BackgroundShin, J., Shin, D. W., Lee, J., Hwang, J., Lee, J. E., Cho, B., & Song, Y. (2022) · BMC Cancer · doi:10.1186/s12885-022-09507-2 · Cited by 47
Calderón, C., Gustems, M., Galán-Moral, R., Muñoz-Sanchez, M., Ostios-García, L., & Jiménez‐Fonseca, P. (2024) · Cancers · doi:10.3390/cancers16050909 · Cited by 40
“Some studies suggest that lung, breast, and melanoma cancer patients have higher fear of recurrence scores, while prostate cancer patients score lower [10,36,39].”
BackgroundResultSmith, A. B., Gao, M., Tran, M. J., Ftanou, M., Jegathees, S., Wu, V. S., Jefford, M., Lynch, F., Dhillon, H. M., Shaw, J., et al. (2023) · Psycho-Oncology · doi:10.1002/pon.6139 · Cited by 34
“The 9‐item FCRI‐SF(14) is the most widely validated and used FCR screening tool in research.(15) However, its length makes it impractical for initial FCR screening in routine clinical care.”
BackgroundMethodInfluentialSelf-citationTutelman, P. R., Chambers, C. T., Heathcote, L. C., Fernandez, C. V., Flanders, A., Patton, M., Schulte, F. S. M., Guilcher, G. M. T., Simard, S., MacLeod, J., et al. (2022) · Psycho-Oncology · doi:10.1002/pon.5879 · Cited by 33
“It has been translated into multiple languages and is widely used in research and clinically.(13) Various FCRI‐SF cut‐off scores for clinical FCR have been proposed (e.”
BackgroundMethodInfluentialParra, G., Soto‐Ruiz, N., Martín‐Rodríguez, L. S., Escalada‐Hernández, P., & García‐Vivar, C. (2023) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2023.151418 · Cited by 34
Tauber, N. M., Zachariae, R., Jensen, A. B., Thewes, B., Skyt, I., Elkjær, E., Butow, P. N., & O’Toole, M. S. (2022) · Psycho-Oncology · doi:10.1002/pon.5772 · Cited by 22
“The scale has been found to be internally consistent, stable over time, with satisfactory construct validity, and responsive to change.(27,28,30) Total scores range from 0–168 with higher scores indicating higher levels of FCR.”
BackgroundSelf-citationFear of Cancer Recurrence in Differentiated Thyroid Cancer Survivors: A Systematic Review
Hampton, J., Alam, A., Zdenkowski, N., Rowe, C. W., Fradgley, E. A., & O’Neill, C. J. (2024) · Thyroid · doi:10.1089/thy.2023.0642 · Cited by 28
“56,82,83 Nevertheless, shorter FCR surveys are more pragmatic for use within a clinical context.”
Smith, A. ‘., Bamgboje‐Ayodele, A., Jegathees, S., Butow, P., Klein, B., Salter, M., Turner, J., Fardell, J., Thewes, B., Sharpe, L., et al. (2024) · Journal of Cancer Survivorship · doi:10.1007/s11764-022-01233-9 · Cited by 23
“This was measured by pre- to post-intervention changes in FCR severity assessed using the FCRI-SF, a widely used and validated subscale of the FCRI [37], across all three time points T0, T1 and T2 [3, 47].”
BackgroundMethodSelf-citationObesity: The Fat Tissue Disease Version of Cancer
Boubertakh, B., Silvestri, C., & Marzo, V. D. (2022) · Cells · doi:10.3390/cells11121872 · Cited by 25
Rha, S. Y., Park, J. S., Choi, Y. Y., Hong, B., & Lee, J. (2022) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2022.102138 · Cited by 23
Ge, M., Sheng, J., Shen, L., Hu, F., Jia, Y., Ur-Rehman, A., Li, W., Lan, J., Liu, P., & Chen, H. (2025) · Psycho-Oncology · doi:10.1002/pon.70077 · Cited by 30
“Regardless of the cancer site, fear for recurrence is recognized as a primary concern among cancer survivors [19], distinct from other forms of psychological distress [20, 21].”
Patel, D. A., Webster, S. N., Dowling, E. J., Knowles, C. R., Lockwood-Taylor, G., Coutts‐Bain, D., Simons, L. E., Diver, E., Chilcot, J., Schapira, L., et al. (2024) · Psycho-Oncology · doi:10.1002/pon.70050 · Cited by 19
Wang, Y., Li, J., Zhai, M., Zhao, Y., & Li, Q. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15164 · Cited by 18
“[5 – 10]/[1 – 20%]).”
BackgroundVandraas, K., Reinertsen, K. V., Smedsland, S., Bøhn, S., Kiserud, C., Falk, R. S., & Lie, H. C. (2023) · Acta Oncologica · doi:10.1080/0284186x.2023.2224052 · Cited by 16
“‘Clinically relevant FCR’, often including moderate and high levels of FCR [23], is characterized by persistent and high degrees of preoccupation and worry concerning disease recurrence and a”
BackgroundFear of Cancer Recurrence in Patients with Sarcoma in the United Kingdom
Petrella, A. R., Storey, L., Hulbert-Williams, N., Fern, L. A., Lawal, M., Gerrand, C., Windsor, R. E., Woodford, J., Bradley, J., O’Sullivan, H., et al. (2023) · Cancers · doi:10.3390/cancers15030956 · Cited by 15
“Research and understanding of FCR have grown rapidly [8]; however, uncertainties remain regarding prevalence by cancer type, underlying mechanisms of action, and the best practices for intervention [9].”
BackgroundMethodResultInfluentialMagnani, C., Smith, A. B., Rey, D., Sarradon‐Eck, A., Préau, M., Bendiane, M., Bouhnik, A., & Mancini, J. (2022) · Journal of Cancer Survivorship · doi:10.1007/s11764-022-01193-0 · Cited by 17
“Consensus regarding thresholds for identifying clinical FCR in more comprehensive measures is also needed [9].”
BackgroundMethodSelf-citationKan, J. M., Dieng, M., Butow, P. N., Mireskandari, S., Tesson, S., Menzies, S. W., Costa, D. S. J., Morton, R. L., Mann, G. J., Cust, A. E., et al. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.661190 · Cited by 14
“Brief measurement tools have shown promise and may reduce the cognitive burden on patients while quickly identifying those with greatest clinical need (Fardell et al., 2018; Rudy et al., 2020; Smith et al., 2020).”
BackgroundSelf-citationAguiar‐Ibáñez, R., McQuarrie, K., Jayade, S. P., Penton, H., DiGiovanni, L., Raina, R., Heisen, M., & Martinez, A. (2024) · Future Oncology · doi:10.1080/14796694.2024.2436342 · Cited by 13
“The prospect of the cancer recurring creates psychological distress, impairs functioning (physical, emotional, cognitive, and social), and decreases overall quality of life [4].”
Bergerot, C. D., Ferreira, L. N., Molina, L. N. M., Pagung, L. B., Pedersen, B. D. S., de Andrade, T. G., Machado, R. H. I., Freitas, A. N. D. S., Barreto, L. H. C. T., de Araújo, L. L., et al. (2022) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2022.111125 · Cited by 16
Self-citationJuggling cancer and life in survivorship: The role of general practitioners
Hart, N. H., Smith, A. B., Hobbs, K., Thamm, C., Gordon, L. G., Crichton, M., & Chan, R. J. (2021) · Australian Journal of General Practice · doi:10.31128/ajgp-04-21-5938 · Cited by 13
Self-citationŞahin, T. K., Şahin, E. A., Gungor, H. N., Güven, D. C., Barışta, İ., & Akın, S. (2025) · Cancer Medicine · doi:10.1002/cam4.70561 · Cited by 12
O'Sullivan, C. C., Larson, N. L., Vierkant, R. A., Smith, M. L., Chauhan, C., Couch, F. J., Olson, J. E., Loprinzi, C. L., & Ruddy, K. J. (2024) · Archives of Public Health · doi:10.1186/s13690-024-01351-z · Cited by 10
“In a survey of younger BC survivors ( ≤ 45 years), increasing age and longer time since diagnosis were linked with lower FCR levels [24] vs in our survey, where increased time since diagnosis was associated with increased distress levels.”
BackgroundSinclair, F., Gillanders, D., Rooney, N., Bonathan, C., Hendry, K., McLoone, P., & Hewitt, C. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-08179-3 · Cited by 9
“There is some controversy over the optimal cut-off point for a clinically meaningful FCR score on this tool, with systematic review of studies encompassing 14,092 people affected by cancer, during or post-treatment, revealing a range of recommended cut-points between 13 and 22 [31].”
MethodBadaghi, N., van Kruijsbergen, M., Prins, J., Kelders, S., Cillessen, L., Compen, F., Donders, R., Kwakkenbos, L., & Speckens, A. (2023) · BMC Psychology · doi:10.1186/s40359-023-01052-2 · Cited by 8
“Fear of cancer recurrence will be assessed using the nine-item Fear of Cancer Recurrence Inventory-severity subscale (FCRI-SF) [26].”
MethodWhich Head and Neck Cancer Patients Are Most at Risk of High Levels of Fear of Cancer Recurrence
Rogers, S. N., Monssen, C., Humphris, G. M., Lowe, D., & Kanatas, A. N. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.671366 · Cited by 13
Clarke, S. T., Murphy, B. M., Hester, R., & Jackson, A. C. (2025) · Behavioral Sciences · doi:10.3390/bs15040479 · Cited by 11
“Since that time, numerous studies have investigated the prevalence, predictors, and impacts of FoRP in cancer and other patient groups (Calderon et al., 2024; Folkerts et al., 2022; Lebel et al., 2020; Luigjes-Huizer et al., 2022; Pang & Humphris, 2021; Smith et al., 2020).”
Badaghi, N., van Kruijsbergen, M., Speckens, A. E. M., Vilé, J., Prins, J. B., Kelders, S. M., & Kwakkenbos, L. (2024) · JMIR Formative Research · doi:10.2196/52338 · Cited by 9
“…the full-scale trial are reported: Hospital Anxiety and Depression Scale [23], severity scale of the Fear of Cancer Recurrence Inventory-Short Form [24,25], fatigue severity subscale of the Checklist Individual Strength [26], rumination subscale of the Rumination and Reflection Questionnaire [27],…”
MethodSavard, J., Filion, C., Brearty, C. M., Caplette‐Gingras, A., Chiquette, J., & Dorval, M. (2024) · Cancer Medicine · doi:10.1002/cam4.6889 · Cited by 11
“The FCRI is the most widely used self-report scale in research 15 and its 9-item severity scale can be used to screen clinical levels of FCR. Shorter screening tools (e.g., one-item questionnaire), that are easier to integrate in routine care, are also being developed.”
MethodYan, Y., Liu, J., Pang, Y. K., Wang, Z., Peng, R., Jiang, D., Yang, Y., Tang, L., & Sun, L. (2024) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-024-04533-y · Cited by 7
Core Fear of Cancer recurrence symptoms in Cancer Survivors: a network approach
Fodor, L. A., Todea, D., & Podina, I. R. (2022) · Current Psychology · doi:10.1007/s12144-022-03500-5 · Cited by 10
van Helmondt, S. J., van der Lee, M. L., Bisseling, E., Lodder, P., & Vries, J. D. (2021) · European Journal of Cancer Care · doi:10.1111/ecc.13431 · Cited by 11
“For most translations, the internal consistency scores of the Reassurance and/or Coping Strategies subscales are slightly lower (but all above 0.70), and for some translations, the test– retest reliability was unsatisfactory (Smith et al., 2020).”
InfluentialSelf-citationVanlaer, N., Dirven, I., Neyns, B., & Rogiers, A. (2024) · Cancers · doi:10.3390/cancers16091638 · Cited by 6
“%) and specificity (75%), to detect clinical FCR [19,20].”
BackgroundClarke, S. T., Grande, M. R. L., Murphy, B. M., Hester, R., & Jackson, A. C. (2024) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.115 · Cited by 9
Liu, J., Griva, K., & Mahendran, R. (2023) · Annals of Behavioral Medicine · doi:10.1093/abm/kaad023 · Cited by 9
Tran, M. J., Jefford, M., Smith, A. B., Lynch, F., Dhillon, H. M., Shaw, J., McDowell, L. J., White, A., Halloran, C., Wiesenfeld, D., et al. (2022) · Pilot and Feasibility Studies · doi:10.1186/s40814-022-01123-y · Cited by 8
“Approximately, 50% of cancer survivors experience moderate-to-high or clinically significant FCR [2, 3].”
BackgroundSelf-citationReed, S. C., Berrett‐Abebe, J., Whitney, R. L., Sarkar, S., & Bell, J. F. (2021) · Journal of Psychosocial Oncology Research and Practice · doi:10.1097/or9.0000000000000064 · Cited by 15
“Despite the clinical cut-off for FCR continuing to be debated and with the understanding that all measurement tools have some shortcomings,([105,106]) we recommend that the Fear of Cancer Recurrence Inventory (FCRI) and FCRI-Short Form (FCRI-SF) be used as high-quality measurement tools for FCR.”
MethodAguiar‐Ibáñez, R., McQuarrie, K., Martinez, A., Penton, H., DiGiovanni, L., Raina, R., Heisen, M., & Jayade, S. P. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00328-4 · Cited by 5
“Following a cancer diagnosis, many patients with early‑stage disease report fearing a recur‑ rence [3].”
InfluentialMacharia, J. M., Raposa, B. L., Sipos, D., Melczer, C., Tóth, Z., & Káposztás, Z. (2023) · Healthcare · doi:10.3390/healthcare11222954 · Cited by 14
“To evaluate FCR, many verified metrics/tools have been created [64].”
BackgroundDix, M., Cohen‐Woods, S., Wassie, M. M., Winter, J. M., Wilson, C. J., Young, G. P., Cock, C., & Symonds, E. L. (2025) · Cancer Medicine · doi:10.1002/cam4.70723 · Cited by 4
“Fear of CRC was measured using a modified version of the Fear of Cancer Recurrence Inventory—Short Form (FCRI-SF), a tool that has displayed good psychometric properties within cancer settings [28].”
Butler, T., Smith, A. B., Pilatti, K., Brown, B., Anderson, K. M., Morris, B., & Garvey, G. (2023) · Current Oncology · doi:10.3390/curroncol30030222 · Cited by 5
“Women reported that heightened FCR was commonly triggered by imminent followup appointments and/or test results, similar to non-Indigenous cancer survivors [25,27,28].”
ResultSelf-citationXu, R. H., Yu, S., Yang, Y., Ng, S. S. M., Xu, B., & Dong, D. (2021) · Disability and Rehabilitation · doi:10.1080/09638288.2021.1985631 · Cited by 5
Miller, D. G., Lapen, K., Dee, E. C., Meske, S. W., Weiss, M. C., Chino, J., & Chino, F. L. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.49809 · Cited by 5
Chen, F., Deng, Y., Li, S., Zhang, Q., Xiao, Z., Knobf, M. T., & Ye, Z. (2025) · Asia-Pacific Journal of Oncology Nursing · doi:10.1016/j.apjon.2025.100763 · Cited by 7
Tran, M. J., Jefford, M., Fua, T. F., Smith, A. B., McDowell, L. J., Dhillon, H. M., Lynch, F., Shaw, J., White, A., Wiesenfeld, D., et al. (2025) · Psycho-Oncology · doi:10.1002/pon.70070 · Cited by 6
Self-citationLee, G., Ahn, A., Lee, D., Kim, T. E., Kong, S., Kang, D., Kim, H. K., Shim, Y. M., & Cho, J. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08505-3 · Cited by 6
“This finding is consistent with previous studies [11, 26–29].”
Taher, R., Carr, N. J., Vanderpuye, N., & Stanford, S. N. (2022) · Journal of Cancer Survivorship · doi:10.1007/s11764-022-01238-4 · Cited by 7
Dehghan, M., Namjoo, Z., Shekarabadi, F. M., Dashtkhaki, M. Z., Ravari, Z. K., Banani, F. K., Sarbanani, F. K., Khandan, B. K., & Zakeri, M. A. (2022) · Cancer Investigation · doi:10.1080/07357907.2022.2082463 · Cited by 3
“According to Smith et al. (2020), between 30.0 and 53.9% of the cancer population (i.e., patients and survivors) appear to experience sub-clinical or clinical FCR (14).”
BackgroundMethodInfluentialMichel, A., Dorval, M., Chiquette, J., & Savard, J. (2024) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-024-00285-5 · Cited by 3
“This rate is higher than those obtained in previous studies of patients treated for cancer (e.g., breast, lung, pancreatic, endometrial) also using the FCRI-S, which ranged from 53.1 to 60.1% [51].”
ResultInfluentialRationale and recommendations for improving early-stage oncology diagnosis, treatment, and access
Aguiar‐Ibáñez, R., Goldschmidt, D., Zhou, Z., Eales, J., Peters, S., Cardoso, F., Ciani, O., Arunachalam, A., Haiderali, A., Roediger, A., et al. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2623775 · Cited by 3
Şahin, T. K., Atalah, F., Köylü, B., Oruç, A. F., Acarbay, A., Karakök, A., Dogan, S., Kıkılı, C. İ., Turhan, G., Emin, G., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1693295 · Cited by 4
“A score of 13 or above on the FCRI-SF has been suggested as a cutofffor at least moderate levels of fear of progression (FoP) requiring attention (29, 30).”
Erul, E., Avcı, A. N., Akkuş, E., Ayas, Ö. F., Danışman, F. B., & Utkan, G. (2025) · Current Oncology · doi:10.3390/curroncol32110592 · Cited by 2
“Specifically, 53.9% were above the ≥ 13 threshold, 43.3% exceeded ≥ 16, and 30.0% met the ≥ 22 criterion [26].”
InfluentialLivingston, P. M., Winter, N., Russell, L., Eric, O., Smith, A. B., Romaniuk, H., Jefford, M., Ugalde, A., Girgis, A., Austin, D., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103373 · Cited by 5
Self-citationBak, R., Junker, T., Jensen, J. B., Pelant, T., Haase, R. N., Zachariae, R. H., & Nielsen, T. K. (2024) · Acta Oncologica · doi:10.2340/1651-226x.2024.40418 · Cited by 2
“Similarly, Luigjes-Huizer et al. [25] and Smith et al. [24] found a significant association between FCR severity and younger age as well as female gender.”
BackgroundInfluentialSelf-citationBrearty, C. M., Bisaillon, L., Dorval, M., Nabi, H., Desbiens, C., Lemieux, J., Théberge, V., Baghdadli, A., Lauzier, S., & Savard, J. (2024) · Current Oncology · doi:10.3390/curroncol31020059 · Cited by 3
“…patient subgroups (breast, lung, pancreatic, and endometrial cancer), which ranged from 53.1% to 60.1% using the same tool and cut-off score [39] and it was also higher than in a recent study conducted among 36 women treated for non-metastatic breast cancer in Quebec during the first wave…”
ResultInfluentialFear of Cancer Recurrence and Unmet Needs in Triple Negative Breast Cancer Survivors
Bae, K. R., & Kim, S. H. (2024) · Asian Oncology Nursing · doi:10.5388/aon.2024.24.3.125 · Cited by 2
Fear of cancer recurrence in males diagnosed with breast cancer
Dalton, K., Waterman, M., Wassersug, R. J., & Garland, S. N. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06307-5 · Cited by 4
Hundal, J., Chen, J., Russell, K. B., Carfang, L., Bedeau, A. J., Giguère, L., Ouattara, M. M., Sehabi, G., Lebel, S., Shen, S., et al. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517396 · Cited by 1
Self-citationIngeman, K., Carstensen, T. B. W., Smith, A. B., Simard, S., Frostholm, L., Ørnbøl, E., Wellnitz, K. B., & Lyhne, J. D. (2026) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-026-01051-y · Cited by 2
“This critique has previously been raised [17], with the argument that survivors cured of cancers with a high likelihood of recurrence may find it challenging to respond to this item.”
InfluentialSelf-citationChen, F., Xiong, Y., Li, S., Zhang, Q., Deng, Y., Xiao, Z., Knobf, M. T., & Ye, Z. (2025) · Current Oncology · doi:10.3390/curroncol32120685 · Cited by 2
“The Fear of Cancer Recurrence Inventory (FCRI) was regarded as one of the most robust instruments with sound psychometric properties for assessing FCR [25].”
Pradhan, P., Sharpe, L., Russell, H., Todd, J., Lichtenthal, W. G., Beard, C., & Butow, P. N. (2025) · Psycho-Oncology · doi:10.1002/pon.70338 · Cited by 1
Preliminary Validation of the Cancer Worry Scale in Pediatric Survivors of Childhood Cancer
Russell, K. B., Patton, M., Verhesen, T., Forbes, C., Stokoe, M., Guilcher, G. M. T., Tomfohr‐Madsen, L. M., & Schulte, F. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31967 · Cited by 1
“…paper evaluating the adapted-language version of the Fear of Cancer Recurrence Inventory—Short Form (FCRI-SF), named the FCRI-C, Tutelman and colleagues’ [9] pediatric sample had a mean FCRI-C score of 10.10, comparatively lower thantheFCRI-SFmeanscoreinadultsamples,recentlyestimated at 15.7 [36].”
InfluentialChiu, H.-C., Lin, C., Shu, B., Lee, K., & Wu, M. (2025) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2025.102859 · Cited by 2
García, D. M. J., Vázquez-Esseso, M. B., Gálvez‐Hernández, C. L., Bazan, J., & Simard, S. (2024) · Anales de Psicología · doi:10.6018/analesps.590721 · Cited by 2
“…that this measure has been translated and validated from French to English, Chinese, Danish, Mandarin, Persian, Turkish, Korean, Dutch and several others (Smith et al., 2020; Shin et al., 2017; van Helmondt, van der Lee & de Vries, 2017); however, the FCRI is not currently available in Spanish.”
BackgroundMethodFear of cancer recurrence in caregivers of paediatric cancer survivors in Singapore
Kamarudin, N., Choo, S. C., Lee, N. K. L., Nashi, N. B., & Lateef, F. (2026) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2026329
Wu, V. S., Crawford-Williams, F. M., Cook, O., Liu, J., Ftanou, M., Philp, S., Taylor, N., David, M., Zakhary, I., Tutton, L., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10491620/v1
Karatlı, S., Karatlı, S. K. Ç., Çelik, S., Eren, T., & Yazılıtaş, D. (2026) · Healthcare · doi:10.3390/healthcare14162665
“Reviews evaluating FCRI-based studies have emphasized that the prevalence of FCR varies substantially depending on the cut-off value used, making direct comparisons between studies difficult [21].”
Allard, D., Mizara, A., & Edginton, T. L. (2026) · Qualitative Health Research · doi:10.1177/10497323261462023
Psilocybin for Fear of Cancer Recurrence
Cho, M., Rosenbaum, D., Hapke, E., & Hales, S. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-11065-3
“The Fear of Cancer Recurrence Inventory (FCRI) remains the most widely used measure, assessing severity, triggers, and functional impact [6].”
Yun, H.-Y., Kang, N., Kim, M., Nam, J., Park, H. Y., Lee, J.-S., Choi, S., Kim, J., Kim, Y. A., Chang, Y. J., et al. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-11047-5
“Overall, 60.87% ( n = 210) had elevated FCR (K-FCRI-SF ≥ 16).”
InfluentialAltıntop, S. E., Barlas, T., Yalçın, M. M., Altınova, A. E., Aktürk, M., Toruner, F. B., Karakoç, M. A., & Cerit, E. T. (2026) · Endocrine · doi:10.1007/s12020-026-04691-8
“In our study, beyond the total FCRI score, all FCRI subscales were similar across ATA risk groups [19, 38].”
Addressing fear of breast cancer recurrence through process-oriented hypnosis
Criswell, S. R. (2026) · American Journal of Clinical Hypnosis · doi:10.1080/00029157.2026.2661685
“The definition, the description of the elements of FCR, and the creation of validated measures of FCR (Smith et al., 2020) have made it easier for clinicians and researchers to study and then report on the effectiveness of treatments for FCR.”
Giguère, L., Kearns, E., Shenthil, S., Mutsaers, B., Harris, C. A., Smith, A. B., Humphris, G. M., Costa, D. S. J., Kogan, C. S., Simard, S., et al. (2026) · Psycho-Oncology · doi:10.1002/pon.70537
Self-citationReliability and validity of the Dutch bodily threat monitoring scale in breast cancer survivors
Overbeke, M. V., Dams, L., Mertens, M. G., Evenepoel, M., Braun, M., Dijck, S. V., Paepe, A. L. D., Tack, E., Meeus, M., Heathcote, L. C., et al. (2026) · Journal of Psychosocial Oncology Research and Practice · doi:10.1097/or9.0000000000000200
Ingeman, K., Lyhne, J. D., Fink, P., Smith, A. B., Frostholm, L., & Carstensen, T. B. W. (2026) · Journal of Cancer Survivorship · doi:10.1007/s11764-026-02058-6
Self-citationNěmčíková, P., Javůrková, A., Raudenská, J., Srobar, S., Musil, V., Simard, S., & Brunerová, L. (2026) · Endocrine · doi:10.1007/s12020-026-04602-x
Badaghi, N., Lubbers, J., Prins, J. B., Kelders, S. M., Speckens, A. E. M., & Kwakkenbos, L. (2026) · Journal of Medical Internet Research · doi:10.2196/79928 · Cited by 1
“Secondary outcomes included the Fear of Cancer Recurrence Inventory [25], the Rumination subscale of the Rumination and Reflection Questionnaire (RRQ) [26], the Fatigue Severity subscale of the Checklist Individual Strength [27], the Five Facet Mindfulness Questionnaire–Short Form (FFMQ-SF) [28],…”
Wang, X., Yuan, M., & Ma, X. (2026) · Research Square · doi:10.21203/rs.3.rs-8587364/v1 · Cited by 1
Adaptation and Validation of the Fear of Blistering Disease Recurrence Inventory
White, M. A., Simard, S., Yale, M., & Tomayko, M. M. (2025) · Dermatology · doi:10.1159/000549920 · Cited by 1
“A meta-analysis of studies reporting FCRI-SF scores among people living with cancer reported a weighted mean score of 15.7/36 [15].”
InfluentialBouhnik, A., Smith, A. B., Bendiane, M., Magnani, C., Rey, D., Préau, M., Sarradon‐Eck, A., & Mancini, J. (2025) · Supportive Care in Cancer · doi:10.1007/s00520-025-10094-8
“Younger age, severity of physical symptoms, psychological distress, and lower quality of life are often associated with higher FCR in cancer survivors (9, 11, 12).”
Self-citationSeo-Hee, C. H. O. I., Kim, Y., & Choe, Y. (2025) · Daehan imsang geon-gang jeungjin hakoeji/Daehan imsang geon'gang jeungjin haghoeji · doi:10.15384/kjhp.2025.00122
“This classification reflects a multidimensional approach to capturing clinically meaningful levels of recur-rence-related fear across multiple domains [10,11].”
Oliveira, J., Neves, M. C., Bártolo, A., Sales, C. M. D., & Monteiro, S. O. M. (2025) · Psycho-Oncologie · doi:10.18282/po4364
Sierra-Murguía, M. A., Bazan-Muñoz, J., Crisóstomo-Rosas, S., Lebel, S., Maheu, C., Rivera-Olvera, I., & Gálvez‐Hernández, C. L. (2025) · Psicooncología · doi:10.5209/psic.101690
Self-citationO'Sullivan, C. C., Larson, N. L., Vierkant, R. A., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3334709/v1
Pereira, L., Nguyen, P., Benea, A., & Townsley, C. A. (2023) · Journal of Psychosocial Oncology · doi:10.1080/07347332.2023.2254755 · Cited by 1
“18 Alternatively, clinicians may assess patients based on a higher FCRI-SF score (≥22) to better identify clinically significant levels of FCR. 8,19 Other measures such as the FCR-4/7, the CARQ-4, or a single-question screening tool can easily be implemented for a broader assessment at follow-up…”
BackgroundPeur de la récidive du cancer en contexte pandémique chez les femmes atteintes d'un cancer du sein
Brearty, C. M., Bisaillon, L., Lauzier, S., & Savard, J. (2023) · Psycause revue scientifique étudiante de l École de psychologie de l Université Laval · doi:10.51656/psycause.v13i1.51849
“S est une des mesures les plus fréquemment utilisées dans la littérature actuelle sur la PRC (Smith et al., 2020).”
BackgroundInfluentialYan, Y., Liu, J., Pang, Y. K., Wang, Z., Peng, R., Jiang, D., Yang, Y., Tang, L., & Sun, L. (2023) · Research Square · doi:10.21203/rs.3.rs-3127348/v1
Varnoosfaderani, N. J., & Amiri‐Ardekani, E. (2023) · Korean Journal of Family Medicine · doi:10.4082/kjfm.22.0183
Taher, R., Stanford, S. N., Carr, N. J., Vanderpuye, N., & Chandrakumaran, K. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057294 · Cited by 1
Metadata
- Authors
- Smith, A. B., Costa, D., Galica, J., Lebel, S., Tauber, N., van Helmondt, S. J., & Zachariae, R.
- Affiliations
- UNSW Sydney (AU)
- The University of Sydney (AU)
- Queen's University (CA)
- University of Ottawa (CA)
- Aarhus University (DK)
- Corresponding author
- Smith, Allan Ben
- ORCID
- Venue
- Psychology Research and Behavior Management
- Publisher
- Informa UK Limited
- Published
- 2020-12
- Volume
- Volume 13
- Pages
- 1257-1268
- ISSN
- 1179-1578 (ISSN-L)
- PMC
- PMC7762428
- OpenAlex
- W3116015896
- Cited by
- 98
- References
- 82
- Citations by year
- 2026: 18 · 2025: 20 · 2024: 16 · 2023: 15 · 2022: 18 · 2021: 11
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Psychology Research and Behavior Management (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Cancer Institute NSW
- Topics
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Childhood Cancer Survivors' Quality of Life
- Social Sciences › Decision Sciences › Management Science and Operations Research › Psychometric Methodologies and Testing
- Keywords
- fear of cancer recurrence, psychometric properties, factor structure, reliability statistics, cross-cultural equivalence, cancer survivors, fear of progression, psychological morbidity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.